McKesson Q2 Beat Drives FY27 Guidance Raise, But Valuation and Litigation Risks Linger

What happened

McKesson reported strong fiscal Q2 results with revenue and profit growth driven by prescription volumes, specialty distribution, and medication access services, and subsequently raised its fiscal 2027 adjusted earnings outlook. The update aligns with the company's strategic focus on higher-margin oncology and specialty platforms, which have been key growth drivers, though growth remains partly acquisition-aided. Despite the operational strength, the shares trade at an elevated valuation with negative book equity and significant opioid litigation liabilities, including a revived $2.5 billion West Virginia suit. The master report had recommended trimming above $880 and waiting for a pullback toward $720, but the latest guidance raise may support a higher floor for the stock. Nevertheless, the core question remains whether organic growth can sustain the 13-16% EPS growth target without reliance on one-time gains and aggressive buybacks.

Implication

Investors should monitor whether the raised FY27 outlook is backed by organic growth in Oncology & Multispecialty rather than acquisitions or one-time items. The stock's valuation continues to embed high expectations, and any revenue miss or litigation development could trigger multiple compression. The ongoing opioid litigation, particularly the revived West Virginia case, remains a significant tail risk that could impact capital returns. While the earnings update is positive, it does not alter the thesis that the stock is fully valued at current levels, and discipline suggests trimming into strength above $880 and revisiting on a pullback toward $720. The next catalysts will be the Q3 results and further details on the Medical-Surgical spin-off, which could provide clarity on the company's long-term earnings power.

Thesis delta

The strong Q2 results and raised FY27 guidance reinforce the bull case but do not resolve the valuation and litigation concerns that underpin the cautious rating. The thesis remains that McKesson is a high-quality compounder but the stock is fully valued, with limited upside over the next 6-18 months. The update marginally increases the probability of the bull scenario, but the core risk-reward still favors trimming into strength and waiting for a better entry.